Tiziana Life Sciences plc (NASDAQ:TLSA) was founded in 1998 and is headquartered in London, England. It has 14 full-time employees. It is a biotechnology company dedicated to discovering and developing new molecules and related therapies to treat the fields of oncology and immunology. Meet the medical needs.
Tiziana Life Sciences plc (TLSA):
The main candidate for immunology of Tiziana Life Sciences plc is Foralumab (TZLS-401) , which is the only fully human anti-cluster definition 3 (anti-CD3) monoclonal antibody (mAbs) in clinical development. MAbs represents a single pure antibody produced by a single clone and is an important class of therapeutic products for the treatment of cancer and autoimmune diseases.
Antibodies produced in animals for use in humans can cause strong immune responses, limit their effectiveness and may cause serious side effects. A process called “humanization” removes most of the animal components of antibodies, thereby reducing the immune response of the human immune system. The complete elimination of other animal materials, such as fully human antibodies, is the ultimate goal to avoid incompatibility with the human immune system.
The main candidate product of Tiziana Life Sciences in the field of oncology is Milciclib (TZLS-201) , which is an oral, bioavailable, small molecule, broad-spectrum inhibitor, mainly targeting cyclin-dependent kinases (CDKs). And sarcoma (Src) family kinases.
CDKs are a family of highly conserved enzymes that are involved in the phosphorylation of specific proteomes that regulate the cell cycle. The cell cycle is a series of events that occur in a cell, leading to the division and replication of its DNA to produce two daughter cells.
Src family kinases are non-receptor tyrosine kinase proteins encoded by the Src gene, which are also involved in regulating cell growth and potential transformation of normal cells into cancer cells.
The mission of Tiziana Life Sciences is to design and provide next-generation treatment and diagnosis of the highly unmet medical needs of oncology and immune diseases by combining a deep understanding of disease biology with clinical development expertise.
Tiziana Life Sciences plc (TLSA) investment:
Tiziana Life Sciences plc (NASDAQ:TLSA) submitted its IPO prospectus on 7/26/2018 and listed on Nasdaq on 11/20/2018 with an issue price of US$9.9. It issued 442,910 shares and raised US$4,384,809.00. The stock code is TLSA. , Underwritten by Laidlaw & Company (UK) Ltd.